Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Johnson & Johnson

Which stock wins in a match-up between these two healthcare giants?

Better Buy: Amgen (AMGN) vs. Johnson & Johnson (JNJ)

Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

3 Investing Facts About Required Minimum Distributions You Need to Know - December 20, 2019

JPMorgan Chase & Co

Mastercard

These stocks could be great sources of dividend income for many years to come.

3 Dividend Stocks That Hiked Their Payouts by More Than 100% in 5 Years

Alector Inc

Fulcrum Therapeutics Inc

Ultragenyx Pharmaceutical

Schnitzer Steel Industries Inc

SAGE Therapeutics

Sarepta Therapeutics

Vertex Pharmaceuticals

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.

8 Biotech Stocks Morgan Stanley Recommends For 2020

UnitedHealth Group

DENTSPLY SIRONA

After a year of sector underperformance, several factors are coalescing to make 2020 a better year for the health care sector, Goldman Sachs said Monday as it added three stocks to its conviction list.

Goldman Sachs Adds Amgen, UnitedHealth, Dentsply Sirona To Conviction List

Health care remains a political hot button. Despite the Affordable Care Act, there remains a push and pull in the industry over which companies can survive and which ones can thrive in the decade ahead.

Goldman Sachs Has 3 Top Health Care Stocks to Outperform in 2020

Biotech can be a risky sector for those interested in healthcare stocks, but Amgen has found a way to manage the risk and reap the rewards.

3 Reasons This Biotech is a Buy for Risk-Averse Investors

The biotech titan is poised for another strong year in 2020.

Here's Why You Should Own Amgen Stock in 2020

The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

Amgen's Osteoporosis Drug Evenity Gets Approval in Europe

Amgen Inc. AMGN, +0.07% said late Wednesday its board hiked the quarterly dividend by 10%.

Amgen board hikes dividend by 10%

Healthpeak's (PEAK) lease amendment and extension with Amgen at the Britannia Oyster Point of the former offers flexibility in addressing lease-expiration issue at this property.

Healthpeak Amends & Extends Lease With Amgen in San Francisco

Boston Scientific

The year-end success of the healthcare sector has led to several strong stocks to buy. Here are three of the best healthcare stocks to buy.

3 Healthcare Stocks to Buy Before the End of 2019

FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.

Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar

Biogen

Which stock wins in a battle between these two big biotechs?

Better Buy:  Biogen vs.  Amgen

Amarin Corporation Plc

Bausch Health Companies Inc

Intra-Cellular Therapies

FDA announcements can make or break a stock. These four events are the most important ones this month.

4 FDA Dates Biotech Investors Should Circle in December

Shares of Amgen are on an upswing after the company won a patent battle over its drug Enbrel against Novartis subsidiary Sandoz. Is it time to buy shares of the massive biotech company?

The Biggest Biotech Just Touched A Record High — Is Amgen Stock A Buy?

Pfizer

Which of these pharma giants is the better buy?

Better Buy: Amgen vs. Pfizer

Novartis's purchase comes with investigational cardiovascular drug inclisiran, a competitor with potential to dethrone Amgen's already embattled Repatha.

Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Up 11.2% Since Last Earnings Report: Can It Continue?

Healthy New Drug Sales And A Refreshed Pipeline Helping Lundbeck Set A Bottom

Amgen Inc: Taking Patent Dynamics Into Account

iShares Nasdaq Biotechnology ETF

Biotech stocks have joined the fourth quarter rally and could post strong gains in the coming months.

Biotech Stocks Awaken From Long Slumber

Novartis

Sanofi

Medicines

Regeneron Pharmaceuticals

Swiss drugmaker Novartis  is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co  as it challenges cardiovascular medicines from Amgen Inc , Sanofi  and Regeneron Pharmaceuticals.

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Bristol-Myers

These two dividend-paying pharma stocks are basically immune to the whims of the broader economy.

2 Stocks to Buy If You're Worried About a Recession

Amgen (AMGN) concludes the pending buyout of Celgene's psoriasis drug Otezla to acquire its worldwide rights. The company also hikes its overall 2019 view.

News for Amgen Stock (AMGN)